Characteristics | B (n = 59) | A (n = 138) | H7N9 (n = 18) | p-value among | |
---|---|---|---|---|---|
(a) | (b) | (c) | (a) and (b) | (a), (b), and (c) | |
Complications | 7 (12) | 16 (12) | 4 (22.2) | 0.957 | 0.411 |
 Shock | 1 (1.7) | 9 (6.5) | 1 (5.6) | 0.289 | 0.315 |
 Acute kidney injury | 5 (8.5) | 11 (8) | 2 (11.1) | 1 | 0.793 |
 Rhabdomyolysis | 1 (1.7) | 1 (0.7) | 1 (5.6) | 0.51 | 0.147 |
Treatment | |||||
 Oxygen therapy, no. (%) | 44 (74.6) | 101 (73.2) | 18 (100) | 0.84 | 0.022 |
 Antiviral treatment, no. (%) | 52 (88) | 152 (93) | 18 (100) | 0.72 | 0.388 |
  Oseltamivir | 36 (69.2) | 70 (56.5) | 0 (0) | 0.114 | < 0.001 |
  Peramivir | 9 (17.3) | 32 (25.8) | 0 (0) | 0.224 | 0.02 |
  Both | 7 (13.5) | 22 (17.7) | 18 (100) | 0.485 | < 0.001 |
Timing from onset of illness to administration of antiviral therapy, median (IQR) (days) | 6 (3–14) | 7 (5–10.8) | 4 (3–8.3) | 0.797 | 0.089 |
 0–2 | 9 (17.6) | 14 (11.3) | 1 (18) | 0.258 | 0.384 |
 3–5 | 12 (23.5) | 31 (25) | 57 (34.8) | 0.837 | 0.091 |
 ≥ 6 | 30 (58.8) | 79 (63.7) | 8 (44.4) | 0.544 | 0.281 |
Timing from administration of antiviral therapy to virus negative, median (IQR) | 11 (6–17.75) | 10 (6–14.5) | 5 (2.8–10) | 0.26 | 0.007 |
Admission to ICU, no. (%) | 4 (6.8) | 27 (19.6) | 15 (83.3) | 0.024 | 0.054 |
Mechanical ventilation | |||||
 Noninvasive | 6 (10.2) | 14 (10.1) | 0 (0) | 0.996 | 0.528 |
 Invasive | 2 (3.4) | 23 (16.7) | 7 (38.9) | 0.001 | 0.001 |
Extracorporeal membrane oxygenation | 0 (0) | 2 (1.4) | 2 (11.1) | 1 | 0.048 |
Blood purification | 4 (6.8) | 3 (2.2) | 2 (11.1) | 0.2 | 0.072 |
Antibiotics | 56 (94.9) | 134 (97.1) | 17 (94.4) | 0.430 | 0.416 |
Antifungal | 22 (37.3) | 42 (30.4) | 13 (72.2) | 0.347 | 0.002 |
Glucocorticoids | 24 (41) | 77 (56) | 18 (100) | 0.052 | < 0.001 |
Clinical outcome | |||||
 Death | 5 (8.5) | 13 (9.4) | 0 (0) | 0.833 | 0.542 |
 Total hospitalization expenses (Yuan), median (IQR) | 18,316.8 (11,111.1–35,750.5) | 25,642.3 (13,184.5–53,805.7) | 66,095.6 (42,450.6–129,574.2) | 0.094 | < 0.001 |